Claims

1. Human NSCLC cell line LD1-0025-200717, deposited under CCTCC No. C2020103.
2. The cell line of claim 1, which comprises the *EGFR* mutations in Exon 20 encoding T790M and C797S as well as the Exon 19 deletion 746_750del.
3. Human NSCLC cell line LD1-0025-200636, deposited under CCTCC No. C202005.
4. Human NSCLC cell line LD1-0025-200694, deposited under CCTCC No. C2020102.
5. The cell line of claim 4, which comprises *EGFR* mutations in Exon 21 encoding L858R.
6. Human NSCLC cell line LD1-0006-215676, deposited under CCTCC No. C2020104.
7. The cell line of claim 6, which comprises *EGFR* mutations in Exons 20 and 21 encoding T790M and L858R.
8. Progeny cell lines derived from human NSCLC cell line of any one of claims 1-7.
9. A reagent comprising the human NSCLC cell line of any one of claims 1-7 or the progeny cell lines of claim 8.
10. A kit comprising the human NSCLC cell line of any one of claims 1-7 or the progeny cell lines of claim 8 or the reagent of claim 9.
11. Use of the cell line of any one of claims 1-7 or the progeny cell lines of claim 8 or the reagent of claim 9 or the kit of claim 10 for generating NSCLC in an immune compromised mammal for evaluating the efficacy of anti-NSCLC drugs, preferably said immune compromised mammal is an immune compromised mouse.
12. A method for producing an animal model, comprising injecting or implanting the human NSCLC cell line of any one of claims 1-7 or the progeny cell lines of claim 8, or the reagent of claim 9 into an animal, preferably said animal is an immune compromised mammal, more preferably an immune compromised mouse.
13. A method for evaluating efficacy of anti-NSCLC drugs, comprising
    (i) contacting one or more candidate drugs with the human NSCLC cell line of any one of claims 1-7 or the progeny cell lines of claim 8, or the reagent of claim 9, or the kit of claim 10,
    (ii) determining the inhibition of cell growth.